Katie Bechman1,2, Mark Yates3,4, Sam Norton3,4, Andrew P Cope3,4, James B Galloway3,4. 1. From the Department of Inflammation Biology, Academic Rheumatology, and Psychology Department, Institute of Psychiatry, King's College London, London, UK. katie.bechman@kcl.ac.uk. 2. K. Bechman, MBCHB, BSC, Department of Inflammation Biology, Academic Rheumatology, King's College London; M. Yates, MBCHB, BSC, Department of Inflammation Biology, Academic Rheumatology, King's College London; S. Norton, PhD, Psychology Department, Institute of Psychiatry, King's College London; A. Cope, PhD, Department of Inflammation Biology, Academic Rheumatology, King's College London; J.B. Galloway, PhD, Department of Inflammation Biology, Academic Rheumatology, King's College London. katie.bechman@kcl.ac.uk. 3. From the Department of Inflammation Biology, Academic Rheumatology, and Psychology Department, Institute of Psychiatry, King's College London, London, UK. 4. K. Bechman, MBCHB, BSC, Department of Inflammation Biology, Academic Rheumatology, King's College London; M. Yates, MBCHB, BSC, Department of Inflammation Biology, Academic Rheumatology, King's College London; S. Norton, PhD, Psychology Department, Institute of Psychiatry, King's College London; A. Cope, PhD, Department of Inflammation Biology, Academic Rheumatology, King's College London; J.B. Galloway, PhD, Department of Inflammation Biology, Academic Rheumatology, King's College London.
Abstract
OBJECTIVE: Understanding the placebo response is critical to interpreting treatment efficacy, particularly for agents with a ceiling to their therapeutic effect, where an increasing placebo response makes it harder to detect potential benefit. The objective of this study is to assess the change in placebo responses over time in rheumatoid arthritis (RA) randomized placebo-controlled trials (RCT) for drug licensing authorization. METHODS: The Cochrane Controlled Trials Register database was searched to identify RCT of biological or targeted synthetic disease-modifying antirheumatic drugs (DMARD) in RA. Studies were excluded if patients were conventional synthetic DMARD (csDMARD)-naive, not receiving background csDMARD therapy, or were biologic experienced. Metaregression model was used to evaluate changes in American College of Rheumatology (ACR) 20, ACR50, and ACR70 treatment response over time. RESULTS: There were 32 trials in total: anti-tumor necrosis factor therapy (n = 15), tocilizumab (n = 4), abatacept (n = 2), rituximab (n = 2), and Janus kinase inhibitors (n = 9). From 1999 to 2018, there was no significant trend in the age or sex of patients in the placebo arm. Disease duration, swollen joint count, and 28-joint count Disease Activity Score using erythrocyte sedimentation rate at baseline all significantly declined over time. There was a statistically significant increase in placebo ACR50 and ACR70 responses (ACR50 β = 0.41, 95% CI 0.09-0.74, p = 0.01; ACR70 β = 0.18, 95% CI 0.04-0.31, p = 0.01) that remained significant after controlling for potential confounders. CONCLUSION: There has been a rise in the placebo response in RA clinical trials over the last 2 decades. Shifting RA phenotype, changes in trial design, and expectation bias are possible explanations for this phenomenon. This observation has important implications when evaluating newer novel agents against established therapies.
OBJECTIVE: Understanding the placebo response is critical to interpreting treatment efficacy, particularly for agents with a ceiling to their therapeutic effect, where an increasing placebo response makes it harder to detect potential benefit. The objective of this study is to assess the change in placebo responses over time in rheumatoid arthritis (RA) randomized placebo-controlled trials (RCT) for drug licensing authorization. METHODS: The Cochrane Controlled Trials Register database was searched to identify RCT of biological or targeted synthetic disease-modifying antirheumatic drugs (DMARD) in RA. Studies were excluded if patients were conventional synthetic DMARD (csDMARD)-naive, not receiving background csDMARD therapy, or were biologic experienced. Metaregression model was used to evaluate changes in American College of Rheumatology (ACR) 20, ACR50, and ACR70 treatment response over time. RESULTS: There were 32 trials in total: anti-tumor necrosis factor therapy (n = 15), tocilizumab (n = 4), abatacept (n = 2), rituximab (n = 2), and Janus kinase inhibitors (n = 9). From 1999 to 2018, there was no significant trend in the age or sex of patients in the placebo arm. Disease duration, swollen joint count, and 28-joint count Disease Activity Score using erythrocyte sedimentation rate at baseline all significantly declined over time. There was a statistically significant increase in placebo ACR50 and ACR70 responses (ACR50 β = 0.41, 95% CI 0.09-0.74, p = 0.01; ACR70 β = 0.18, 95% CI 0.04-0.31, p = 0.01) that remained significant after controlling for potential confounders. CONCLUSION: There has been a rise in the placebo response in RA clinical trials over the last 2 decades. Shifting RA phenotype, changes in trial design, and expectation bias are possible explanations for this phenomenon. This observation has important implications when evaluating newer novel agents against established therapies.
Entities:
Keywords:
AMERICAN COLLEGE OF RHEUMATOLOGY RESPONSE; OUTCOME MEASURES; PLACEBO; RHEUMATOID ARTHRITIS; STUDY DESIGN; SYSTEMATIC REVIEW
Authors: Joel Kremer; Zhan-Guo Li; Stephen Hall; Roy Fleischmann; Mark Genovese; Emilio Martin-Mola; John D Isaacs; David Gruben; Gene Wallenstein; Sriram Krishnaswami; Samuel H Zwillich; Tamas Koncz; Richard Riese; John Bradley Journal: Ann Intern Med Date: 2013-08-20 Impact factor: 25.391
Authors: Josef S Smolen; Andre Beaulieu; Andrea Rubbert-Roth; Cesar Ramos-Remus; Josef Rovensky; Emma Alecock; Thasia Woodworth; Rieke Alten Journal: Lancet Date: 2008-03-22 Impact factor: 79.321
Authors: Edward C Keystone; Arthur F Kavanaugh; John T Sharp; Hyman Tannenbaum; Ye Hua; Leah S Teoh; Steven A Fischkoff; Elliot K Chartash Journal: Arthritis Rheum Date: 2004-05
Authors: P Emery; A Deodhar; W F Rigby; J D Isaacs; B Combe; A J Racewicz; K Latinis; C Abud-Mendoza; L J Szczepanski; R A Roschmann; A Chen; G K Armstrong; W Douglass; H Tyrrell Journal: Ann Rheum Dis Date: 2010-05-20 Impact factor: 19.103
Authors: Edward Keystone; Désireé van der Heijde; David Mason; Robert Landewé; Ronald Van Vollenhoven; Bernard Combe; Paul Emery; Vibeke Strand; Philip Mease; Chintu Desai; Karel Pavelka Journal: Arthritis Rheum Date: 2008-11
Authors: Karel Pavelka; Zoltán Szekanecz; Nemanja Damjanov; Branimir Anić; Matija Tomšič; Vadim Mazurov; Marija Maksimovic; Orsolya Nagy; Jerzy Świerkot; Tzvetanka Petranova; Tiina Veldi; Asta Baranauskaitė; Catalin Codreanu; Daina Andersone; Roy Fleischmann Journal: Drugs Context Date: 2020-10-19
Authors: Bernard Combe; Alan Kivitz; Yoshiya Tanaka; Désirée van der Heijde; J Abraham Simon; Herbert S B Baraf; Uma Kumar; Franziska Matzkies; Beatrix Bartok; Lei Ye; Ying Guo; Chantal Tasset; John S Sundy; Angelika Jahreis; Mark C Genovese; Neelufar Mozaffarian; Robert B M Landewé; Sang-Cheol Bae; Edward C Keystone; Peter Nash Journal: Ann Rheum Dis Date: 2021-01-27 Impact factor: 19.103
Authors: Margaret E Gruen; Jamie A E Myers; Jezaniah-Kira S Tena; Csilla Becskei; Dawn M Cleaver; B Duncan X Lascelles Journal: J Vet Intern Med Date: 2021-11-01 Impact factor: 3.333